{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T20:49:13Z","timestamp":1773953353242,"version":"3.50.1"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1097\/mjt.0b013e31818d3f67","type":"journal-article","created":{"date-parts":[[2009,1,13]],"date-time":"2009-01-13T08:13:54Z","timestamp":1231834434000},"page":"74-85","source":"Crossref","is-referenced-by-count":26,"title":["Diuretics: An Update on the Pharmacology and Clinical Uses"],"prefix":"10.1097","volume":"16","author":[{"given":"Pramod","family":"Reddy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arshag D","family":"Mooradian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R5-14-20210202","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJM199904153401507","article-title":"Genetic disorders of renal electrolyte transport.","volume":"340","author":"Scheinman","year":"1999","journal-title":"N Engl J Med"},{"key":"R7-14-20210202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/joe.1.06017","article-title":"The new biology of aldosterone.","volume":"186","author":"Connell","year":"2005","journal-title":"J Endocrinol"},{"key":"R8-14-20210202","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/ki.1991.228","article-title":"Binding inhibitors restore furosemide potency in tubule fluid containing albumin.","volume":"40","author":"Kirchner","year":"1991","journal-title":"Kidney Int"},{"key":"R9-14-20210202","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0161-6420(81)35041-6","article-title":"Acetazolamide and urolithiasis.","volume":"88","author":"Kass","year":"198","journal-title":"Ophthalmology"},{"key":"R10-14-20210202","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3181\/00379727-91-22159","article-title":"Production of hepatic coma by a carbonic anhydrase inhibitor diamox.","volume":"91","author":"Webster","year":"1956","journal-title":"Proc Soc Exp Biol Med"},{"key":"R11-14-20210202","doi-asserted-by":"crossref","first-page":"F11","DOI":"10.1152\/ajprenal.00119.2002","article-title":"Loop diuretics: from the Na-K-2Cl transporter to clinical use.","volume":"284","author":"Shankar","year":"2003","journal-title":"Am J Physiol Renal Physiol"},{"key":"R12-14-20210202","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/00003495-199549010-00009","article-title":"Torasemide: an update of its pharmacological properties and therapeutic efficacy.","volume":"49","author":"Dunn","year":"1995","journal-title":"Drugs"},{"key":"R13-14-20210202","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/ki.1987.246","article-title":"Comparison of loop diuretics in patients with chronic renal insufficiency.","volume":"32","author":"Voelker","year":"1987","journal-title":"Kidney Int"},{"key":"R14-14-20210202","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1046\/j.1523-1755.1999.00298.x","article-title":"Coadministration of albumin and furosemide in patients with the nephrotic syndrome.","volume":"55","author":"Fliser","year":"1999","journal-title":"Kidney Int"},{"key":"R15-14-20210202","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1681\/ASN.V1251010","article-title":"Effects of albumin\/furosemide mixtures on responses to furosemide in hypoalbuminemic patients.","volume":"12","author":"Chalasani","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"R16-14-20210202","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1042\/cs0840627","article-title":"Iso-oncotic volume expansion in the nephrotic syndrome.","volume":"84","author":"Ribelink","year":"1993","journal-title":"Clin Sci"},{"key":"R17-14-20210202","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0022-2143(99)90202-0","article-title":"Urinary thiamin excretion in the rat: effects of furosemide, other diuretics and volume load.","volume":"134","author":"Lubetsky","year":"1999","journal-title":"J Lab Clin Med"},{"key":"R18-14-20210202","first-page":"69","article-title":"Diuretic use: a risk for subclinical thiamine deficiency in elderly patients.","volume":"4","author":"Suter","year":"2000","journal-title":"J Nutr Health Aging"},{"key":"R19-14-20210202","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1097\/00007611-199909000-00003","article-title":"Long-term diuretic therapy in hypertensive patients: effects on serum homocysteine, vitamin B6, vitamin B12, and red blood cell folate concentrations.","volume":"92","author":"Morrow","year":"1999","journal-title":"South Med J"},{"key":"R20-14-20210202","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0002-9343(99)80349-0","article-title":"Improved left ventricular function after thiamine supplementation in patients with congestive heart failure receiving long-term furosemide therapy.","volume":"98","author":"Shimon","year":"1995","journal-title":"Am J Med"},{"key":"R22-14-20210202","first-page":"271","article-title":"Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action.","volume":"25","author":"Puscas","year":"1999","journal-title":"Drugs Exp Clin Res"},{"key":"R23-14-20210202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-103-1-1","article-title":"Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure.","volume":"103","author":"Francis","year":"1985","journal-title":"Ann Intern Med"},{"key":"R24-14-20210202","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/0016-5085(87)90616-0","article-title":"Immediate effects of furosemide on renal hemodynamics in chronic liver disease with ascites.","volume":"92","author":"Daskalopoulos","year":"1987","journal-title":"Gastroenterology"},{"key":"R25-14-20210202","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1001\/archotol.1993.01880190054011","article-title":"Furosemide ototoxicity is enhanced in analbuminemic rats.","volume":"119","author":"Rybak","year":"1993","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"R26-14-20210202","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0030-6665(20)30770-2","article-title":"Ototoxicity of loop diuretics.","volume":"26","author":"Rybak","year":"1993","journal-title":"Otolaryngol Clin North Am"},{"key":"R27-14-20210202","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa022963","article-title":"Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics.","volume":"349","author":"Strom","year":"2003","journal-title":"N Engl J Med"},{"key":"R28-14-20210202","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"R29-14-20210202","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.HYP.29.1.8","article-title":"Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS).","volume":"29","author":"Grimm","year":"1997","journal-title":"Hypertension"},{"key":"R30-14-20210202","first-page":"S90","article-title":"Edema in pregnancy.","volume":"51","author":"Davison","year":"1997","journal-title":"Kidney Int"},{"key":"R31-14-20210202","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/ki.1994.298","article-title":"Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure.","volume":"46","author":"Fliser","year":"1994","journal-title":"Kidney Int"},{"key":"R32-14-20210202","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1053\/euhj.2001.2729","article-title":"Antihypertensive therapy and the risk of malignancies.","volume":"22","author":"Grossman","year":"2001","journal-title":"Eur Heart J"},{"key":"R33-14-20210202","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1523-1755.2005.67190.x","article-title":"Risk factors for renal cell carcinoma: hypertension or diuretics?","volume":"67","author":"Messerli","year":"2005","journal-title":"Kidney Int"},{"key":"R34-14-20210202","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/0016-5085(83)90198-1","article-title":"Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system.","volume":"84","author":"Perez-Ayuso","year":"1983","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"R35-14-20210202","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00004836-198100031-00016","article-title":"Diuresis in the ascitic patient: a randomized controlled trial of three regimens.","volume":"3","author":"Fogel","year":"1981","journal-title":"J Clin Gastroenterol"},{"key":"R36-14-20210202","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/0002-9343(87)90156-2","article-title":"Unpredictability of clinical evaluation of renal function in cirrhosis. Prospective study.","volume":"82","author":"Papadakis","year":"1987","journal-title":"Am J Med"},{"key":"R37-14-20210202","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/archinte.1994.00420020117013","article-title":"Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis.","volume":"154","author":"Caregaro","year":"1994","journal-title":"Arch Intern Med"},{"key":"R38-14-20210202","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/0016-5085(87)90120-X","article-title":"Altered furosemide pharmacokinetics in chronic alcoholic liver disease with ascites contributes to diuretic resistance.","volume":"92","author":"Pinzani","year":"1987","journal-title":"Gastroenterology"},{"key":"R39-14-20210202","first-page":"198","article-title":"Potassium-sparing diuretics.","volume":"10","author":"Horisberger","year":"1987","journal-title":"Ren Physiol"},{"key":"R40-14-20210202","first-page":"222A","article-title":"Detection of diuretic-resistance or diuretic-sensitivity by spot urine Na\/K ratios.","volume":"36","author":"Stiehm","year":"2002","journal-title":"Hepatology"},{"key":"R41-14-20210202","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1055\/s-2007-1007362","article-title":"Refractory ascites.","volume":"13","author":"Runyon","year":"1993","journal-title":"Semin Liver Dis"},{"key":"R42-14-20210202","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","article-title":"Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.","volume":"102","author":"Zannad","year":"2000","journal-title":"Circulation"},{"key":"R43-14-20210202","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure.","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"R44-14-20210202","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0002-9149(99)80353-1","article-title":"Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease.","volume":"76","author":"Barr","year":"1995","journal-title":"Am J Cardiol"},{"key":"R45-14-20210202","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0002-9149(00)00729-3","article-title":"Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy.","volume":"85","author":"Ramires","year":"2000","journal-title":"Am J Cardiol"},{"key":"R46-14-20210202","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","article-title":"Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure.","volume":"101","author":"Farquharson","year":"2000","journal-title":"Circulation"},{"key":"R48-14-20210202","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"R49-14-20210202","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"key":"R50-14-20210202","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","article-title":"Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.","volume":"40","author":"Krum","year":"2002","journal-title":"Hypertension"},{"key":"R51-14-20210202","first-page":"514","article-title":"Eplerenone: the first selective aldosterone receptor antagonist for the treatment of hypertension.","volume":"37","author":"Coleman","year":"2002","journal-title":"Formulary"},{"key":"R52-14-20210202","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2165\/00003495-200767060-00002","article-title":"Therapeutic potential of vasopressin receptor antagonists.","volume":"67","author":"Ali","year":"2007","journal-title":"Drugs"},{"key":"R53-14-20210202","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1161\/01.CIR.0000159340.93220.E4","article-title":"Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure.","volume":"111","author":"Sackner-Bernstein","year":"2005","journal-title":"Circulation"},{"key":"R54-14-20210202","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","article-title":"Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure.","volume":"291","author":"Gheorghiade","year":"2004","journal-title":"JAMA"},{"key":"R55-14-20210202","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/gut.23.7.625","article-title":"Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hepatic failure.","volume":"23","author":"Canalese","year":"1982","journal-title":"Gut"},{"key":"R56-14-20210202","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/archinte.1982.00340140065013","article-title":"Mannitol intoxication in patients with renal failure.","volume":"142","author":"Borges","year":"1982","journal-title":"Arch Intern Med"},{"key":"R57-14-20210202","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1056\/NEJM200007273430403","article-title":"Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.","volume":"343","author":"Colucci","year":"2000","journal-title":"N Engl J Med"},{"key":"R58-14-20210202","first-page":"1531","article-title":"Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial.","volume":"287","year":"2002","journal-title":"JAMA"},{"key":"R59-14-20210202","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S0735-1097(01)01818-6","article-title":"Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure.","volume":"39","author":"Silver","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R60-14-20210202","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1001\/jama.293.15.1900","article-title":"Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials.","volume":"293","author":"Sackner-Bernstein","year":"2005","journal-title":"JAMA"},{"key":"R61-14-20210202","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.ahj.2006.07.002","article-title":"Short and long-term mortality with nesiritide.","volume":"152","author":"Arora","year":"2006","journal-title":"Am Heart J"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00045391-200901000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T20:37:43Z","timestamp":1632947863000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-200901000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e31818d3f67","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}